IKZF1 and plasma cell myeloma: The pomalidomide-based PROTAC 38 (Figure 7) reduced CDK4 and CDK6 levels in multiple myeloma (MM) cell lines at 100 nM concentration, but also degraded the Ikaros (IKZF1) and Aiolos (IKZF3) transcription factors.